Gustavo H Kijak
Overview
Explore the profile of Gustavo H Kijak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kijak G, Ahani B, Arbetter D, Chuecos F, Gopalakrishnan V, Beloor J, et al.
Infect Dis Ther
. 2023 Nov;
12(12):2691-2707.
PMID: 37914983
Introduction: AZD7442 (tixagevimab/cilgavimab) comprises neutralising monoclonal antibodies (mAbs) that bind to distinct non-overlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Viral evolution during mAb therapy...
2.
Tuffy K, Ahani B, Aksyuk A, Avila M, Brady T, Kijak G, et al.
J Infect Dis
. 2023 Jun;
228(8):1055-1059.
PMID: 37280116
Background: We report spike protein-based lineage and AZD7442 (tixagevimab/cilgavimab) neutralizing activity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants identified from breakthrough infections in the PROVENT preexposure prophylaxis trial....
3.
Roe T, Brady T, Schuko N, Nguyen A, Beloor J, Guest J, et al.
Microbiol Spectr
. 2023 Mar;
:e0033323.
PMID: 36877050
Therapeutic anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (MAbs) provide immunosuppressed and vulnerable populations with prophylactic and treatment interventions against coronavirus disease 2019 (COVID-19). AZD7442 (tixagevimab-cilgavimab) is a...
4.
Crowell T, Kijak G, Sanders-Buell E, OSullivan A, Kokogho A, Parker Z, et al.
Antivir Ther
. 2020 Mar;
24(8):595-601.
PMID: 32125280
Background: Across sub-Saharan Africa, men who have sex with men (MSM) and transgender women (TGW) have disproportionately poor HIV treatment outcomes. Stigma and criminalization create barriers to health-care engagement and...
5.
Naluyima P, Lal K, Costanzo M, Kijak G, Gonzalez V, Blom K, et al.
J Immunol
. 2019 Sep;
203(8):2210-2221.
PMID: 31519862
HIV-1 infection expands large populations of late-stage differentiated CD8 T cells that may persist long after viral escape from TCR recognition. In this study, we investigated whether such CD8 T...
6.
Tovanabutra S, Sirijatuphat R, Pham P, Bonar L, Harbolick E, Bose M, et al.
Cells
. 2019 Aug;
8(8).
PMID: 31443253
HIV-1 disseminates to a broad range of tissue compartments during acute HIV-1 infection (AHI). The central nervous system (CNS) can serve as an early and persistent site of viral replication,...
7.
Billings E, Heipertz R, Varleva T, Sanders-Buell E, OSullivan A, Bose M, et al.
PLoS One
. 2019 May;
14(5):e0217063.
PMID: 31136611
HIV-1 strain diversity in Bulgaria is extensive and includes contributions from nearly all major subtypes and the Circulating Recombinant Forms (CRF): 01_AE, 02_AG, and 05_DF. Prior to this study, HIV-1...
8.
Billings E, Kijak G, Sanders-Buell E, Ndembi N, OSullivan A, Adebajo S, et al.
J Acquir Immune Defic Syndr
. 2019 May;
81(5):578-584.
PMID: 31107298
Background: HIV-1 circulating recombinant forms (CRF) containing subtype B are uncommon in sub-Saharan Africa. Prevalent infections observed during enrollment of a prospective study of men who have sex with men...
9.
Kijak G, Sanders-Buell E, Pham P, Harbolick E, Oropeza C, OSullivan A, et al.
Biomol Detect Quantif
. 2019 Mar;
17:100080.
PMID: 30923677
The analysis of HIV-1 sequences has helped understand the viral molecular epidemiology, monitor the development of antiretroviral drug resistance, and design candidate vaccines. The introduction of single genome amplification (SGA)...
10.
Kroon E, Pham P, Sirivichayakul S, Trichavaroj R, Colby D, Pinyakorn S, et al.
AIDS
. 2018 Aug;
32(16):2373-2381.
PMID: 30096068
Objective: To assess transmission characteristics in a predominantly MSM cohort initiating antiretroviral therapy (ART) immediately following diagnosis of acute HIV-1infection (AHI). Methods: A longitudinal study (2009-2017) was performed in participants...